[EN] 2 - (PYRIDIN- 2 -YL) -QUINAZOLINE DERIVATIVES AND THEIR USE AS MICROBICIDES [FR] DÉRIVÉS DE 2-(PYRIDIN-2-YL)-QUINAZOLINE ET LEUR UTILISATION EN TANT QUE MICROBICIDES
[EN] CONDENSED PYRIDINES AND PYRIMIDINES AND THEIR USE AS ALK-5 RECEPTOR LIGANDS<br/>[FR] PYRIDINES ET PYRIMIDINES CONDENSEES ET LEUR UTILISATION EN TANT QUE LIGANDS DU RECEPTEUR ALK-5
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2004065392A1
公开(公告)日:2004-08-05
Therapeutically active substituted quinoline and quinazoline compounds derivatives of formula (I) wherein X is N or CH, Y is NH, N (alkyl) or NH-CH2, and R2 and R3 are specified heterorings, the use thereof in therapy, particularly in the treatment or prophylaxis of disorders characterised by overexpression of transforming growth factor β (TGF-β), and pharmaceutical compositions for use in such therapy are disclosed.
[EN] 2 - (PYRIDIN- 2 -YL) -QUINAZOLINE DERIVATIVES AND THEIR USE AS MICROBICIDES<br/>[FR] DÉRIVÉS DE 2-(PYRIDIN-2-YL)-QUINAZOLINE ET LEUR UTILISATION EN TANT QUE MICROBICIDES
申请人:SYNGENTA PARTICIPATIONS AG
公开号:WO2012066122A1
公开(公告)日:2012-05-24
Compounds of formula I wherein the other substituents R1, R2, R3, R4, R5 and R6 are as defined in claim 1, and their use as microbicides.
2-PYRIDIN-2-YL-QUINAZOLINE DERIVATIVES AS POTASSIUM CHANNEL MODULATING AGENTS FOR THE TREATMENT OF RESPIRATORY DISEASES
申请人:Eriksen Birgitte L.
公开号:US20090306102A1
公开(公告)日:2009-12-10
This invention relates to novel pyridinyl-quinazoline derivatives and their use as potassium channel modulating agents. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels.
Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors
作者:F. Gellibert、M.-H. Fouchet、V.-L. Nguyen、R. Wang、G. Krysa、A.-C. de Gouville、S. Huet、N. Dodic
DOI:10.1016/j.bmcl.2009.02.087
日期:2009.4
Starting from quinazoline 3a, we designed potent and selective ALK5 inhibitors over p38MAP kinase from a rational drug design approach based on co-crystal structures in the human ALK5 kinase domain. The quinazoline 3d exhibited also in vivo activity in an acute rat model of DMN-induced liver fibrosis when administered orally at 5 mg/kg (bid). (c) 2009 Elsevier Ltd. All rights reserved.
Copper-catalyzed transformation of ketones to amides via C(CO)–C(alkyl) bond cleavage directed by picolinamide
cleavage of the C(CO)–C(alkyl) bond leading to C–N bondformation with a chelation-assist from N-containing directing groups is described. Inexpensive Cu(II)-acetate serves as a convenient catalyst for the transformation. This method highlights the emerging strategy to transform unactivated alkyl ketones into amides in organicsynthesis and provides a new strategy for C–C bond cleavage.